| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
AVL-3288 targets the α7 nicotinic acetylcholine receptor (α7 nAChR). It acts as a positive allosteric modulator, enhancing the receptor's response to acetylcholine. By modulating α7 nAChR activity, it influences cognitive function, neuroprotection, and inflammation. AVL-3288 is a selective α7 nAChR modulator.
|
|---|---|
| ln Vitro |
CCMI (Compound 6) is a strong and specific positive allosteric modulator of α7 nAChR. It significantly increases the positive modulation of α7 nAChR agonist-induced currents without binding to or activating α7 nAChR through the orthosite [1].
In vitro, AVL-3288 enhances the activity of the α7 nAChR in response to acetylcholine. It has been shown to improve cognitive function in preclinical models. Its effects on neuronal signaling and neuroprotection have been characterized in various cell-based assays. AVL-3288 is a potent and selective α7 nAChR modulator. |
| ln Vivo |
In vivo, AVL-3288 has been studied for its potential in treating cognitive disorders. It has shown efficacy in preclinical models of schizophrenia and Alzheimer's disease. AVL-3288 improves cognitive function and has neuroprotective effects. It is an orally bioavailable compound.
|
| Enzyme Assay |
The activity of AVL-3288 can be assessed using cell-based functional assays. Cells expressing the α7 nAChR are treated with acetylcholine and varying concentrations of AVL-3288. The potentiation of receptor-mediated calcium influx or other downstream signaling events is measured. The EC₅₀ for potentiation is determined from dose-response curves.
|
| Cell Assay |
To evaluate the cellular effects of AVL-3288, neuronal cells or cells expressing the α7 nAChR are treated with the compound. The enhancement of acetylcholine-induced calcium influx and neuronal signaling is measured. The effects on cell viability, neuroprotection, and inflammation are assessed.
|
| Animal Protocol |
In vivo studies with AVL-3288 typically involve administration to animal models via oral routes. In models of cognitive disorders (e.g., schizophrenia, Alzheimer's disease), the compound's effects on cognitive function, neuroinflammation, and neurodegeneration are assessed. Pharmacokinetic parameters, such as oral bioavailability and brain penetration, are also characterized.
|
| ADME/Pharmacokinetics |
AVL-3288 has a molecular formula and weight that are not specified in the available literature. Its CAS number is 917837-54-8. It is a positive allosteric modulator of the α7 nAChR. It is soluble in DMSO and other organic solvents. The purity is typically >98%. It should be stored according to the manufacturer's instructions.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for AVL-3288 are not extensively detailed in the available literature. However, its use in animal models at effective doses suggests a degree of tolerability. As with all research compounds, standard safety precautions should be taken when handling AVL-3288. It is intended for research use only and is not for human consumption.
|
| References | |
| Additional Infomation |
AVL-3288 (CCMI) is a positive allosteric modulator of the α7 nicotinic acetylcholine receptor. It enhances the activity of the α7 nAChR and has been studied for its potential in treating cognitive disorders such as schizophrenia and Alzheimer's disease. AVL-3288 is a research tool for studying α7 nAChR function and developing cognitive enhancers.
|
| Molecular Formula |
C19H15CL2N3O2
|
|---|---|
| Molecular Weight |
388.248
|
| Exact Mass |
387.054
|
| CAS # |
917837-54-8
|
| Related CAS # |
917837-54-8;
|
| PubChem CID |
16005981
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.412±0.06 g/cm3(Predicted)
|
| Boiling Point |
605.4±55.0 °C
|
| LogP |
5.527
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
501
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NOC(=C1)/C(=C/NC2=CC=C(C=C2)Cl)/C(=O)NC3=CC=C(C=C3)Cl
|
| InChi Key |
VMAKIACTLSBBIY-BOPFTXTBSA-N
|
| InChi Code |
InChI=1S/C19H15Cl2N3O2/c1-12-10-18(26-24-12)17(11-22-15-6-2-13(20)3-7-15)19(25)23-16-8-4-14(21)5-9-16/h2-11,22H,1H3,(H,23,25)/b17-11-
|
| Chemical Name |
(Z)-3-(4-chloroanilino)-N-(4-chlorophenyl)-2-(3-methyl-1,2-oxazol-5-yl)prop-2-enamide
|
| Synonyms |
Anvylic-3288 UCI-4083AVL-3288 UCI-4083UCI4083CCMIXY-4083 Anvylic-3288AVL3288XY-4083 XY 4083 XY4083 UCI4083 UCI 4083 CCMI
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~257.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5757 mL | 12.8783 mL | 25.7566 mL | |
| 5 mM | 0.5151 mL | 2.5757 mL | 5.1513 mL | |
| 10 mM | 0.2576 mL | 1.2878 mL | 2.5757 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA